CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH (CHARTER) EXTENSION

CNS HIV 抗逆转录病毒治疗效果研究（章程）扩展

• 批准号: 8737536
• 负责人: IGOR GRANT
• 金额: $ 102.72万
• 依托单位: CALIFORNIA UNIV SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-16 至 2015-09-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8737536
• 关键词: AIDS neuropathy; Address; Anti-Retroviral Agents; Biological Preservation; Blood; Brain; California; Cells; Cognition; DNA; Disease; Evolution; Failure; Funding; Goals; HIV; Highly Active Antiretroviral Therapy; Image; Impaired cognition; Individual; Laboratories; Light; MRI Scans; Magnetic Resonance Imaging; Medical; Morbidity - disease rate; Nerve Fibers; Nervous System Trauma; Nervous system structure; Neurocognitive; Neurologic; Neuropathy; Participant; Performance; Peripheral Nervous System Diseases; Plasma; Population; Procedures; Protocols documentation; RNA; Research; Research Personnel; Research Project Grants; Role; Schwann Cells; Site; Texas; Universities; Washington; antiretroviral therapy; base; cohort; density; follow-up; medical schools; mortality; neuropsychological; performance site; quality assurance; virus genetics; white matter

The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) was funded in 2002 with the aim of exploring the changing presentation of HIV neurological complications in the context of highly active antiretroviral therapy (HAART). The six performance sites of CHARTER (Johns Hopkins University, Mt. Sinai Medical School, University of California at San Diego, University of Texas Medical Branch at Galveston, University of Washington, Washington University at St. Louis), representing a diverse participant pool as well as investigators with expertise in various aspects of NeuroAIDS, were able to standardize neuromedical, neuropsychological, psychiatric, neuropathy, and imaging protocols along with on-going quality assurance procedures. Two key conclusions to emerge from the CHARTER project are that HIV-Associated Neurocognitive Disorders (HAND) and peripheral neuropathy remain highly prevalent despite effective HIV treatments that have significantly reduced mortality and non-neurologic morbidities. In CHARTER Extension, 180 participants (30 per site) from the original CHARTER longitudinal cohort have been selected for further study based on the goal of shedding light on CSF virologic failure, low-level HIV replication, worsening cognition and abnormal white matter, as well on-going peripheral neuropathy. These individuals will be assessed annually using well-established neuropsychological, neuromedical, laboratory, and neuropathy assessments. A subset of participants will complete annual brain MRI scans.

CNS HIV抗逆转录病毒治疗效果研究（CHARTER）于2002年获得资助，目的是探索在高效抗逆转录病毒治疗（HAART）背景下HIV神经系统并发症的变化。查特的六个表演场地（约翰霍普金斯大学，山。Sinai医学院、加州大学圣地亚哥分校、德克萨斯大学医学分支加尔维斯顿分校、华盛顿大学、华盛顿大学圣路易斯分校），代表了多样化的参与者以及在NeuroAIDS各个方面具有专业知识的研究者，能够标准化神经医学、神经心理学、精神病学、神经病和成像方案沿着持续的质量保证程序。CHARTER项目得出的两个关键结论是，尽管有效的HIV治疗显著降低了死亡率和非神经系统疾病，但HIV相关神经认知障碍（HAND）和周围神经病变仍然非常普遍。在CHARTER扩展研究中，基于阐明CSF病毒学失败、低水平HIV复制、认知恶化和异常白色物质以及持续性周围神经病变的目标，从原始CHARTER纵向队列中选择了180例受试者（每个研究中心30例）进行进一步研究。每年将使用成熟的神经心理学、神经医学、实验室和神经病评估对这些个体进行评估。一部分参与者将完成年度脑部MRI扫描。